scholarly journals Relationship between platelet derived growth factor receptor‐β and Alzheimer’s biomarkers in a racially diverse, high‐risk cohort

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Brittany Butts ◽  
Scott Miners ◽  
Patrick G. Kehoe ◽  
William T. Hu ◽  
Hanfeng Huang ◽  
...  
Keyword(s):  
Growth Factor ◽  
High Risk ◽  
Growth Factor Receptor ◽  
Platelet Derived Growth Factor ◽  
Racially Diverse ◽  
High Risk Cohort

Preoperative platelet-derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation in high-risk localized prostate cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5141-5141
Author(s):  
P. Mathew ◽  
C. Pettaway ◽  
L. Pisters ◽  
D. Williams ◽  
P. Troncoso ◽  
...  
Keyword(s):  
Growth Factor ◽  
High Risk ◽  
Treatment Failure ◽  
Specific Antigen ◽  
Fluid Pressure ◽  
Growth Factor Receptor ◽  
Inhibitor Therapy ◽  
Platelet Derived Growth Factor ◽  
Gleason Grade ◽  
Androgen Ablation

5141 Background: Reduction in tumor interstitial fluid pressure with platelet-derived growth factor receptor (PDGFR) inhibitor therapy in experimental systems improves drug delivery and the therapeutic index of taxane chemotherapy (Pietras, Cancer Research, 2002). We hypothesized that PDGFR inhibitor therapy with imatinib mesylate combined with androgen ablation (AA) and docetaxel (D) induces pathological complete responses (pCR) in high-risk localized prostate adenocarcinoma (PC) prior to radical prostatectomy and pelvic lymph node dissection (RP). Methods: Thirty six men with PC ≥T2 disease or Gleason grade 8–10 or serum prostate-specific antigen (PSA) > 20 ng/ml or cT2b and PSA >10 ng/ml and Gleason 7 disease (AJCC, 1992), without radiological evidence of metastases, were planned to receive intramuscular leuprolide, imatinib 600mg orally daily, and weekly D 30 mg/m2 on D1, 8, 15, 22 q42 for three cycles (18 weeks) before RP [β (0.02, 1.98) prior on the possibility of pCR]. Unresectable pelvic nodal disease, post-operative PSA > 0.2 ng/ml or administration of post-operative radiation or AA were defined as treatment failure. Results: Between 6–03 and 9–04, 39 men were registered; median age 57 years (range, 44–71); 35 Caucasian, 2 Hispanic, 4 African-American. Risk factors included T3 disease (22/39), Gleason 8–10 disease (31/39), PSA > 20 ng/ml (12/39). Three men were ineligible or declined therapy; 29/36 (80%) received three cycles of therapy; 7/36 (20%) discontinued therapy related to toxicity. Grade 3–4 toxicity included rash (n=3), diarrhea (n=5), fatigue (n=3), neutropenia (n=2), hepatic (n=1). Severe or unexpected surgical complications were not encountered. No pCRs were defined; 15/36 (42%) have PSA < 0.2 ng/ml [12/36 (33%), <0.1 ng/ml] at 24 months and 13/36 (36%) met definition for treatment failure. Conclusions: The addition of the PDGFR inhibitor imatinib to pre-operative AA and D, although feasible, did not induce pCR in PC. [Table: see text]

scholarly journals 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized forc-kit and platelet-derived growth factor receptor α gene alterations

Cancer ◽  
2005 ◽  
Vol 104 (1) ◽  
pp. 159-169 ◽  
Author(s):  
Federica Perrone ◽  
Elena Tamborini ◽  
Gian Paolo Dagrada ◽  
Federica Colombo ◽  
Lorena Bonadiman ◽  
...  
Keyword(s):  
Growth Factor ◽  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
Growth Factor Receptor ◽  
Platelet Derived Growth Factor ◽  
Stromal Tumors ◽  
9P21 Locus ◽  
Gene Alterations
Sign in / Sign up

Export Citation Format

Share Document